Transforming postpartum depression treatment with neurosteroids
A new study in Neuropsychopharmacology delves into the mechanisms of action of brexanolone, the first FDA-approved, rapid-acting antidepressant specifically for postpartum depression (PPD). The research highlights brexanolone's potential anti-inflammatory effects and its impact on GABAA receptors, offering insights into its efficacy and suggesting avenues for further study.
Source: news-medical.net